Clopidogrel Pharmacogenomics Project

Completed · Phase 2

Conditions studied: Disease Susceptibility

In brief

Loss-of-function mutation of the gene encoding the CYP450 2C19 enzyme has emerged as a likely determinant of resistance to clopidogrel therapy. The primary hypothesis of the proposed research is that among patients with confirmed loss-of-function alleles of the CYP2C19 gene, increasing the maintenance clopidogrel dose from 75 to 150 mg will result in significant reduction in the rate of measured clopidogrel resistance defined by multiple measures of platelet function

Key facts

Study ID
NCT01097343
Run by
University of North Carolina, Chapel Hill
People needed
50
Starts
2010-03-01
Expected to finish
2011-05-01
Last updated by the study team
2017-12-12

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.